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Abstract
To explore the largely unknown etiology of small intestine cancer, we examined
metabolic factors and risk of small intestine cancer overall and by subtypes. Among
404 220 women and 403 265 men in six European cohorts, we applied Cox regression
with adjustment for smoking and body mass index (BMI), to calculate sex-specific hazard
ratios (HRs) of small intestine cancer by levels of BMI, mean arterial pressure (MAP) and
plasma total cholesterol, triglycerides and glucose. We also calculated HRs for these fac-
tors combined (metabolic score; MetS) and used Wald test statistics to investigate
pairwise interactions between metabolic factors on risk. We also performed analyses
separately per subtype (neuroendocrine tumors [NETs] and adenocarcinomas). During a
median follow-up of 16.9 years, 144 women and 195 men were diagnosed with small
intestine cancer, including 184 NETs and 99 adenocarcinomas. Among men, no main
associations or interactions between metabolic factors were observed in relation to the
risk of small intestine cancer. Among women, triglycerides were positively and linearly
associated with risk (HR per standard deviation [SD]: 1.23, 95% confidence interval [CI]:
1.04-1.46), and a positive association was also observed for the MetS (HR per SD: 1.25,
95% CI: 1.02-1.52). Positive interactions were observed among women between triglyc-
erides and cholesterol (P = .0005), and between MAP and glucose (P = .009), on risk.
Glucose was positively associated with adenocarcinomas among women. This large, pro-
spective study suggests that elevated triglycerides, and metabolic factors in interaction,
confer an increased risk of small intestine cancer among women, but not among men.
Abbreviations: 40-y, The Age 40-program; BMI, body mass index; CI, confidence interval; HR, hazard ratio; ICD, International Classification of Diseases; ICD-O, International Classification of
Diseases-Oncology; log, logarithms naturalis; MAP, mean arterial pressure; Me-Can, Metabolic syndrome and Cancer project; MetS, metabolic score; MPP, Malmö Preventive Project; NCS, The
Norwegian County Study; Oslo, The Oslo study I cohort; siNETs, small intestine neuroendocrine tumors; VHM&PP, The Vorarlberg Health Monitoring and Prevention Program; VIP, The
Västerbotten Intervention Project.
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1 | INTRODUCTION
Rare cancers make up approximately 20% to 25% of all incident
cancers,1,2 but the incidence of each specific cancer is very low. Small
intestine cancer is one such cancer, for which the incidence rates has
increased during the past decades in high-income countries.3 However,
the type of tumors primarily driving the increase varies between coun-
tries. In the United States, the increase has primarily been seen for
small intestine neuroendocrine tumors (siNETs) (previously carcinoid
tumors),4 whereas in the Netherlands there has been an increase pri-
marily of adenocarcinomas.5 Moreover, cancer of the small intestine is
often detected at a late stage with a poor prognosis, and the 5-year
overall survival was only 48% to 65% in 2012 to 2016 in the Nordic
countries.6 This urges for more knowledge about the causes of small
intestine cancer, which is currently very limited. There is, however,
some evidence that genetic and lifestyle factors may be related to risk.3
Obesity and related metabolic factors have been associated with
increased risks of many cancer forms.7-10 About 4% to 6% of all can-
cers worldwide, and 13% of obesity-related cancers in adults, have
been attributed to high body mass index (BMI, kg/m2).11 In relation to
cancer of the small intestine, one large prospective study with 1162
incident cases, showed an increased risk for overweight and obesity
among men, but not among women.12 Other prospective studies have
been much smaller (nevents ≤ 237)13-18 and in a recent umbrella review
of obesity and cancer risk, evidence was considered insufficient to
make any conclusions for cancer of the small intestine.19 Additionally,
cardiometabolic risk factors, summarized as the metabolic syndrome,
could be independent risk factors or on the pathway between obesity
and small intestine cancer. During the past years evidence was accu-
mulating for an association between cancer and metabolic syndrome;
a constellation of obesity and insulin resistance, hypertension and
dyslipidemia,.9,10 However, there are virtually no studies on the rela-
tionship between these factors and cancer of the small intestine alto-
gether, or in histopathological subtypes.
The aim of our study was to investigate single metabolic factors
and a combined metabolic score (MetS) in relation to the risk of small
intestine cancer overall and separately for adenocarcinoma and siNET
in a large pooled European cohort study with long follow-up.
2 | MATERIALS AND METHODS
2.1 | Study population
The Metabolic syndrome and Cancer project (Me-Can) 2.0 is an expan-
sion of Me-Can 1.0, which has previously been described in detail.20
Me-Can 2.0 pools data from six cohorts in Austria (Vorarlberg Health
Monitoring and Prevention Program [VHM&PP], 1985-2005), Norway
(Norwegian Counties Study, 1974-1988; Age 40 Program [40y],
1985-1999; Oslo Study I [Oslo I], 1972-1973) and Sweden (Västerbotten
Intervention Project [VIP], 1985-ongoing; Malmö Preventive Project
[MPP], 1974-1992). Compared to Me-Can 1.0, on which Me-Can publica-
tions in 2009 to 2015 are based, Me-Can 2.0 includes one less cohort
(Cohort of Norway) but additional individuals and health observations in
the VIP between the years 2006 and 2014, and in the VHM&PP between
the years 2003 and 2005. All participants have undergone one or more
health examination(s), which included measurements of height, weight,
blood pressure, and plasma concentrations of glucose, total cholesterol
and triglycerides, as previously described in detail.20,21 Data on smoking
status were collected by questionnaires, except in the VHM&PP, where
data was recorded during interview.
The selection of the study population is shown in Figure S1. Out of
843 531 individuals with 1 557 855 health examinations (observations) in
Me-Can 2.0, we excluded 36 046 individuals (141 227 observations), with
the majority of exclusions (133 031 observations, 94%) performed due to
a prevalent cancer at the time of health examination, a nonfasting status
with unknown fasting time in the VHM&PP before the year 1988, or
missing fasting status. Among the remaining 807 485 individuals
(1 416 628 observations), we selected the first observation for our study.
2.2 | Exposures
We calculated BMI as weight (kg)/height2 (m) and mean arterial pres-
sure (MAP) as (systolic blood pressure + 2 × diastolic blood
What's new?
Little is known about the etiology of small intestine cancer. In
this study, there was little evidence for an association of body
mass index with small intestine cancer. However, strong posi-
tive associations were found for triglycerides and a metabolic
score in women, and glucose was further positively associated
with adenocarcinoma of the small intestine in women.
A healthy lifestyle preventing metabolic aberrations may pre-
vent small intestine cancer in women. Cancers of the small
intestine are often detected at a late stage with a poor progno-
sis. Thus it would be helpful to understand etiological factors
that lead to these cancers. In this large, prospective study, the
authors found strong positive associations between small
intestine cancer and triglycerides, glucose, or metabolic
scores—but only among women. BMI had little effect in either
sex. These results indicate that lifestyle changes that reduce
metabolic aberrations may help reduce the risk of small intes-
tine cancer in women.
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pressure)/3. These factors, total cholesterol and log-transformed
values of triglycerides and glucose, were divided into quartiles and
were also standardized by (individual level-mean level)/SD into z-
scores with a mean value of zero and a SD of one. The creation of
quartiles and z-standardization were performed separately by cohort,
sex and fasting time. A MetS was constructed by standardizing the
sum of component-wise z-scores, similar to previous Me-Can studies.
2.3 | Outcomes
Cancer cases and deaths were identified through linkages with
national cancer and cause of death registries.20 For identification of
emigration status (except in Austria), the cohorts were linked to the
respective national population register. Follow-up ended on
31 December 2012, in Norway, and on 31 December 2014, in Swe-
den and Austria.
Cancer cases were coded according to the International Classifi-
cation of Diseases (ICD) codes. Cancers of the small intestine were
defined as ICD-7 152 and ICD-10 C17. The subtype adenocarcinoma
was defined as ICD-Oncology (O)-3 codes 8140, 8145, 8210, 8261,
8263, 8480, 8482 and 8490, and siNETs were defined as 8156, 8240,
8241, 8246 and 8249.16
2.4 | Statistical analysis
Due to a differential association by sex between BMI and the risk of
small intestine cancer in the largest study to date,12 we performed all
analyses separately by sex. All Norwegian individuals included in our
study were also included in Reference 12, but with shorter follow-up.
Cox regression models with age as the time metric were fitted to
obtain hazard ratios (HRs) with 95% confidence intervals (95% CIs) for
metabolic factors in quartiles and for these factors and the MetS per
TABLE 1 Baseline characteristics of the 807 485 individuals in the study
Men Women
Cases Total cohort Cases Total cohort
Individuals, N 195 403 265 144 404 220
Age at baseline, years, mean (SD) 46.4 (8.6) 43.0 (8.8) 48.0 (9.7) 42.9 (9.6)
Cohort, N (%)
OSLO 12 (6.2%) 17 708 (4.4%) — —
NCS 25 (12.8%) 44 136 (10.9%) 22 (15.3%) 42 490 (10.5%)
40-y 84 (43.1%) 191 393 (47.5%) 50 (34.7%) 207 710 (51.4%)
VHM&PP 27 (13.9%) 80 957 (20.1%) 38 (26.4%) 94 023 (23.3%)
VIP 18 (9.2%) 48 941 (12.1%) 18 (12.5%) 50 373 (12.5%)
MPP 29 (14.9%) 20 130 (5.0%) 16 (11.1%) 9624 (2.4%)
Fasting time, hours, N (%)
<8 118 (60.5%) 246 150 (61.0%) 72 (50.0%) 244 842 (60.6%)
≥8 77 (39.5%) 157 115 (39.0%) 72 (50.0%) 159 378 (39.4%)
BMI, kg/m2, mean (SD) 25.8 (3.2) 25.6 (3.4) 24.8 (4.1) 24.6 (4.3)
MAP, mm Hg, mean (SD) 100.9 (11.5) 98.7 (11.3) 96.6 (12.7) 93.5 (12.1)
Glucose, mmol/L, median (IQR) 5.3 (4.9-5.8) 5.2 (4.7-5.8) 5.2 (4.8-5.8) 5.1 (4.6-5.6)
Cholesterol, mmol/L, mean (SD) 5.9 (1.1) 5.8 (1.2) 5.8 (1.5) 5.5 (1.1)
Triglycerides, mmol/L, median (IQR) 1.7 (1.2-2.4) 1.6 (1.1-2.3) 1.3 (0.9-1.6) 1.1 (0.8-1.6)
Smoking status, N (%)
Never 66 (33.9%) 155 746 (38.6%) 74 (51.4%) 194 719 (48.2%)
Former 57 (29.2%) 110 945 (27.5%) 35 (24.3%) 93 892 (23.2%)
Current 72 (36.9%) 136 574 (33.9%) 35 (24.3%) 115 609 (28.6%)
Histology, N (%)
Neuroendocrine tumors (NETs) 107 (54.9%) 77 (53.5%)
Adenocarcinoma 52 (26.7%) 47 (32.6%)
Other 36 (18.5%) 20 (13.9%)
Notes: Glucose, cholesterol and triglycerides are all in mmol/L. Glucose and triglycerides are log-transformed.
Abbreviations: 40-y, The Age 40-program; BMI, body mass index (kg/m2); MAP, mean arterial pressure = [(systolic blood pressure + diastolic blood
pressure*2)/3] (mm Hg); MPP, The Malmö Preventive Project; NCS, The Norwegian County Study; Oslo, The Oslo study I cohort; VHM&PP, The
Vorarlberg Health Monitoring and Prevention Program; VIP, The Västerbotten Intervention Project.
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F IGURE 1 Hazard ratio (95% confidence interval) of small intestine cancer (N = 214) across levels of metabolic factors, by sex. The models
were adjusted for smoking status and fasting status, stratified by cohort and categories of birth year
4 NAGEL ET AL.
SD increment. Participants were followed from baseline until their
first cancer diagnosis, emigration or death, whichever occurred first.
All models were stratified by cohort and categories of birth year, and
adjusted models additionally included BMI (except when BMI or the
MetS was the exposure) and smoking status (never, former, current
smokers) as covariables. P-values for linear trends across quartiles of
metabolic factors were derived from Wald test statistics for each met-
abolic factor included as a continuous quartile variable (ranked 1-4) in
the model. We also investigated the shape of the association across
the full exposure range of each metabolic factor using penalized
splines with three degrees of freedom, and the same strata and
adjustments as previously described.
We evaluated cohort and smoking interactions with metabolic fac-
tors and the MetS in relation to risk of small intestine cancer, using the
Wald statistics of product terms of cohort and each metabolic factor or
the MetS as z-score. As the HR for the MetS and small intestine cancer
among women appeared greater than the sum of each individual com-
ponent, we also performed Wald tests of interaction for the product
term of each pairwise combination of metabolic factors as continuous z-
scores. Furthermore, subtypes were analyzed in a similar way as above.
The results for adenocarcinoma and siNETs by sex are presented.
The data were analyzed using the statistical software package
SAS release 9.4 (SAS Institute, Cary, NC), and spline analyses were
performed using R version 3.5.1 (R Foundation for Statistical Comput-
ing, Vienna, Austria).
3 | RESULTS
The 403 265 men in the study were on average 43.0 (SD 8.8) years
old and had a mean BMI of 25.6 (SD 3.4) kg/m2 at baseline, and the
404 220 women were on average 42.9 (SD 9.6) years old and had a
mean BMI of 24.6 (4.3) kg/m2 (Table 1). During a median 16.9 years
of follow-up, 195 men and 144 women were diagnosed with a cancer
of the small intestine; 184 with siNET, 99 with adenocarcinoma and
56 with small intestine cancer of other or unknown type.
Analysis of the shape of the association between metabolic fac-
tors and the risk of small intestine cancer virtually showed no associa-
tions across the range of exposures, with the exception of a u-shaped
association for cholesterol among women, and a positive linear associ-
ation for triglycerides among women (Figure 1). Triglycerides were
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adjusted analyses of quartiles (HR, fourth vs first quartile, 1.88, 95%
CI 1.09-3.26, P for trend = .03) (Table 2) and z-scores (HR per SD,
1.23, 95% CI 1.04-1.46) (Table 3). Despite the lack of association
between other single metabolic factors and risk among women, a
strong positive association was found for the MetS in the continuous
model (HR per SD, 1.25, 95% CI 1.02-1.52) and by quartiles (HR,
fourth vs first quartile, 2.74, 95% CI 1.17-6.42, P for trend = .03).
Pairwise interaction tests between z-scores of single metabolic factors
showed significant positive associations between triglycerides and
cholesterol (P = .0005) and between glucose and MAP (P = .009) in
women (Table S1). There were no associations between single meta-
bolic factors or the MetS and risk of small intestine cancer
among men.
The associations between metabolic factors and small intestine
cancer risk did not differ by cohort or smoking status (P for interaction
≥.05 for all).
In relation to subtypes, glucose concentrations were positively
associated with adenocarcinoma in women (HR per SD, 1.39, 95% CI
1.07-1.79 and in trend for the MetS (1.31, 95% CI 0.93-1.85) (Table 4;
Tables S2 and S3). No other associations were observed in relation to
adenocarcinoma or siNETs in women or men.
4 | DISCUSSION
This large prospective cohort study of metabolic factors and small
intestine cancer showed a positive linear association between triglyc-
eride levels and the risk of small intestine cancer in women. Moreover,
triglycerides and total cholesterol, and MAP and glucose, interacted
positively in women, resulting in a strong positive association
between the MetS and risk of small intestine cancer. The MetS and
glucose were further positively associated with adenocarcinoma of
the small intestine in women. No associations were observed
among men.
Apart from BMI, we are not aware of other studies investigating
the relation between metabolic factors and risk of small intestine can-
cer. A rare cancer, such as small intestine cancer, requires a large sam-
ple size and/or long follow-up to acquire a sufficient number of
events, which we did have through the pooling of six European
cohorts. Follow-up for cancer incidence and mortality was long and
virtually complete in our study through record linkages with high-
quality national registers.20 Yet, the modest number of small intestine
cancers, histological subtypes in particular, remains the main limitation
of our study, which resulted in limited statistical power and potentially
false positive or negative findings. For example, the positive associa-
tions for glucose among women, and BMI among men, were fairly lin-
ear and nearly reached statistical significance, supporting potentially
true positive associations, as previously reported for BMI among
men.12 Moreover, although we accounted for smoking and BMI
(where appropriate) in our analyses, the results might still be con-
founded by other factors such as lifestyle and sociodemographic fac-
tors not available to us. In lack of more specific markers of body
fatness and lipoproteins, respectively, our study was limited to the
use of BMI and total cholesterol level.
Among women, we found a positive association between triglyc-
eride levels and risk of small intestine cancer. Such association does
find some support in experimental studies. For example, Min mice fea-
ture high concentration of serum triglycerides, and these have been
found to accumulate lipids in intestinal polyps,22 and oxidant-related
triglycerides in these mice have been found to be increased in the
course of intestinal polyp formation.23 However, the biological reason
for a positive association between triglycerides and small intestine
cancer among women, but not among men, is unclear. In our study,
cholesterol was not associated with the risk of small intestine cancer,
but interacted positively with triglycerides on risk among women. Sex
differences in lipid and lipoprotein metabolism contribute to sex dif-
ferences in cardio-vascular risk. Complex mechanisms including hor-
monal effects mediated by genes on X chromosome are involved.24
These sex-specific mechanisms may also be involved in cancer risk.
We speculate that sex hormones may partially underlie the observed
interaction between cholesterol and triglycerides among women, and
a differential association between triglycerides and small intestine
cancer between men and women. However, the sex differences
observed in our study require further investigation.
The by far largest prospective study to date on BMI and risk of
small intestine cancer (n = 1162), which had some overlap with
TABLE 3 Hazard ratio (95% confidence interval) of cancer of the small intestine for continuous z-score of metabolic factors, single and
combined (MetS) in 403 265 men and 404 220 women
Exposure
Men (N = 195 cases) Women (N = 144 cases)
Crude HR (95% CI)a Adjusted HR (95% CI)b Crude HR (95% CI)a Adjusted HR (95% CI)b
BMI 1.11 (0.96-1.28) 1.11 (0.97-1.28) 0.96 (0.81-1.14) 0.96 (0.81-1.15)
Mean arterial pressure 1.09 (0.95-1.26) 1.07 (0.93-1.24) 0.99 (0.84-1.17) 1.00 (0.84-1.20)
Log Glucose 0.98 (0.82-1.18) 0.97 (0.80-1.16) 1.13 (0.94-1.35) 1.14 (0.95-1.37)
Cholesterol 0.99 (0.86-1.14) 0.97 (0.84-1.12) 0.95 (0.81-1.13) 0.96 (0.81-1.13)
Log Triglycerides 1.08 (0.94-1.25) 1.05 (0.90-1.22) 1.19 (1.02-1.40) 1.23 (1.04-1.46)
MetS 1.07 (0.88-1.28) 1.06 (0.88-1.28) 1.25 (1.02-1.52) 1.25 (1.02-1.52)
Abbreviations: BMI, body mass index; CI, confidence interval; MetS, metabolic score; HR, hazard ratio.
aCalculated from Cox regression models, with age as time scale, stratified by cohort and categories of birth year.
bAdditionally adjusted for smoking status and BMI (except z-score of BMI and MetS).
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participants of the current study, showed a positive association in
men, but not in women, similar to the pattern observed in our study
as well as for studies of colorectal cancer.12 Another cohort study
with 237 cases of small intestine cancer showed a positive association
overall, but did not investigate the association separately among men
and women.16 That study, like ours, suggested a positive, albeit non-
significant, association between BMI and carcinoid tumors only. Other
prospective studies have been substantially smaller.13-18 The mecha-
nistic pathways that would potentially link obesity to small intestine
cancers, specifically among men and for carcinoid tumors, are unclear.
Possible mechanisms include changes in underlying pathogenetic
pathways including metabolic factors, hormones, including sex-
hormones and inflammatory factors.25 Obesity leads to a number of
pathophysiologic changes including dyslipidemia, hyperglycemia and
inflammation,26-28 which have been suggested to promote tumor
development and growth.28 In colon cancer, the largest proportion of
the association of adiposity was mediated by high-density lipoprotein
cholesterol, non-high-molecular-weight adiponectin and soluble leptin
receptor.29 Differences in the association between men and women
were attributed to reactive oxygen metabolites and C-peptide.29
However, a mechanistic pathway through lipids and glucose specifi-
cally among men are not supported by our results.
Despite that, no other metabolic factor than triglycerides was
positively associated with small intestine cancer among women, a
strong positive association was observed for the MetS, suggesting
synergistic positive effects of individual metabolic factors. Interac-
tion tests showed pairwise interactions between four of the meta-
bolic factors on risk, which has never been observed before in
relation to any cancer form investigated in the Me-Can project.
Future studies will show whether these findings apply also to other
populations.
In conclusion, in this large prospective cohort study, increasing
triglyceride levels and a MetS comprising five metabolic factors were
associated with an increased risk of small intestine cancer in women.
Positive interactions were observed between several metabolic fac-
tors on risk among women. In contrast, no associations were observed
among men. Our findings are novel, and further studies are
warranted.
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